Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: A case report

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1359-1363

  Ikenouchi, Atsuko ^a   Yoshimura, Reiji ^a   Ikemura, Naomi ^a   Utsunomiya, Kensuke ^a   Mitoma, Masae ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

3 Methoxy 4 hydroxyphenylglycol; Brain derived neurotrophic factor; Delirium; Homovanillic acid; Systemic lupus erythematosus

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; CYCLOPHOSPHAMIDE; HOMOVANILLIC ACID; LITHIUM CARBONATE; PREDNISOLONE; RISPERIDONE; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; BLOOD LEVEL; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; DELIRIUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HOSPITAL ADMISSION; HUMAN; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PSYCHOSIS; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; HOMOVANILLIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; METHOXYHYDROXYPHENYLGLYCOL; PSYCHOTIC DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33747088855     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.03.006     Document Type: Article

References (29)

1. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. Fourth edition (2000), American Psychiatric Association, Washington (DC) Text revision (DSM-IV-TR)
2. Currier G.W., and Simpson G.M. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J. Clin. Psychiatry 62 (2001) 153-157
3. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state"; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
4. Hall R.C.W., Popkin M.K., Stickney S.K., and Gardner E.R. Presentation of the steroid psychoses. J Nerv Ment Dis 167 (1979) 229-236
5. Han C.S., and Kim Y.K. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45 (2004) 297-301
6. Hashimoto K., Shimizu E., and Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev 45 (2004) 104-114
7. Horikawa N., Yamazaki T., Miyamoto K., Kurosawa A., Oiso H., Matsumoto F., et al. Treatment for delirium with risperidone: results of a prospective open trial with 10 patients. Gen Hosp Psychiatry 25 (2003) 289-292
8. Kakihara S., Yoshimura R., Shinkai K., Matsumoto C., Goto M., Kaji K., et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20 (2005) 71-78
9. Karege F., Schwald M., and Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelet. Neurosci Lett 328 (2002) 261-264
10. Lewin G.R., and Barde Y.A. Physiology of neurotrophins. Annu Rev Neurosci 19 (1996) 289-317
11. Lewis D.A., and Smith R.E. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord 5 (1983) 319-332
12. Nakamura J., Uchimura N., Yamada S., and Nakazawa Y. Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on derilium. Int Clin Psychopharmacol 12 (1997) 147-152
13. Nakamura J., Yoshimura R., Okuno T., Ueda N., Hachida M., Yasumoto K., et al. Association of plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol, natural killer call activity and delirium in postoperative patients. Int Clin Psychopharmacol 16 (2001) 339-343
14. Nishimura K., Omori M., Horikawa N., Tanaka E., Furuya T., and Harigai M. Risperidone in the treatment of acute confusional state (delirium) due to neuropsychiatric lupus erythematosus: case report. Int J Psychiatry Med 33 (2003) 299-303
15. Nockher W.A., and Renz H. Neurotrophins in inflammatory lung diseases: modulators of cell differentiation and neuroimmune interactions. Cytokine Growth Factor Rev 14 (2003) 559-578
16. Pan W., Banks W.A., Fasold M.B., Blush J., and Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37 (1998) 1553-1561
17. Parellada E., Baeza I., de Pablo J., and Martinez G. Risperidone in the treatment of patients with delirium. J Clin Psychiatry 65 (2004) 348-353
18. Schuhmann B., Dietrich A., Sel S., Hahn C., Klingenspor M., Renz H., et al. A role for brain-derived neurotrophic factor in B cell development. J Neuroimmunol 163 (2005) 15-23
19. Schulte-Herbrüggen O., Nassenstein C., Lommatzsch M., Quarcoo D., Renz H., and Braun A. Tumor necrosis factor-α and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol 160 (2005) 204-209
20. Shlomchik M.J., Madaio M.P., and Ni D. The role of B cells in Ipr/Ipr-induced antoimmunity. J Exp Med 180 (1994) 1295-1306
21. The American College of Rheumatology. Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42 (1999) 599-608
22. Trzepacz P.T., Mittal D., Torres R., Kanary K., Norton J., and Jimerson N. Validation of the delirium rating scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 13 (2001) 229-242
23. Vega J.A., Garcia-Suarez O., Hannestad J., Perez-Perez M., and Germana A. Neurotrophins and the immune system. J Anat 203 (2003) 1-19
24. Warnatz K., Peter H.H., Schumacher M., Wiese L., Prasse A., Petschner F., et al. Infectious CNS disease as a different diagnosis in systemic rheumatic disease: three case reports and a review of the literature. Ann Rheum Dis 62 (2003) 50-57
25. Yoshimura R., Nakamura J., Ueda N., and Terao T. Effect of risperidone on plasma free-3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 15 (2000) 175-180
26. Yoshimura R., Ueda N., Shinkai K., and Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18 (2003) 107-111
27. Yoshimura R., Nakamura J., Shinkai K., and Ueda N. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 611-616
28. Yoshimura R., Nakamura J., Shinkai K., Goto M., Yamada Y., Kaji K., et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychiopharmacol 20 (2005) 243-248
29. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133 (1978) 429-435